310 related articles for article (PubMed ID: 32525247)
1. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
2. Chalcone Derivatives: Role in Anticancer Therapy.
Ouyang Y; Li J; Chen X; Fu X; Sun S; Wu Q
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208562
[TBL] [Abstract][Full Text] [Related]
3. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer.
WalyEldeen AA; Sabet S; El-Shorbagy HM; Abdelhamid IA; Ibrahim SA
Chem Biol Interact; 2023 Jan; 369():110297. PubMed ID: 36496109
[TBL] [Abstract][Full Text] [Related]
4. Current scenario of chalcone hybrids with antibreast cancer therapeutic applications.
Wang H; Zhu J; Zhang Q; Tang J; Huang X
Arch Pharm (Weinheim); 2024 May; 357(5):e2300640. PubMed ID: 38227398
[TBL] [Abstract][Full Text] [Related]
5. Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview.
Xiao J; Gao M; Diao Q; Gao F
Curr Top Med Chem; 2021; 21(5):348-362. PubMed ID: 33092509
[TBL] [Abstract][Full Text] [Related]
6. Recent Progresses in Chalcone Derivatives as Potential Anticancer Agents.
Yang J; Lv J; Cheng S; Jing T; Meng T; Huo D; Ma X; Wen R
Anticancer Agents Med Chem; 2023; 23(11):1265-1283. PubMed ID: 36825723
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Activity of Natural and Synthetic Chalcones.
Constantinescu T; Lungu CN
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768736
[TBL] [Abstract][Full Text] [Related]
8. Chalcone Scaffolds as Anticancer Drugs: A Review on Molecular Insight in Action of Mechanisms and Anticancer Properties.
Shukla S; Sood AK; Goyal K; Singh A; Sharma V; Guliya N; Gulati S; Kumar S
Anticancer Agents Med Chem; 2021; 21(13):1650-1670. PubMed ID: 33238850
[TBL] [Abstract][Full Text] [Related]
9. Natural Chalcones and Their Derivatives Target the Tumor Microenvironment in Colon Cancer.
Malla RR; Siragam S; Dadi V; Seetini B
Crit Rev Immunol; 2022; 42(6):27-39. PubMed ID: 37082949
[TBL] [Abstract][Full Text] [Related]
10. Heterocyclic chalcone analogues as potential anticancer agents.
Sharma V; Kumar V; Kumar P
Anticancer Agents Med Chem; 2013 Mar; 13(3):422-32. PubMed ID: 22721390
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities.
Srinivasan B; Johnson TE; Lad R; Xing C
J Med Chem; 2009 Nov; 52(22):7228-35. PubMed ID: 19883086
[TBL] [Abstract][Full Text] [Related]
12. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Xu Z; Zhao SJ; Liu Y
Eur J Med Chem; 2019 Dec; 183():111700. PubMed ID: 31546197
[TBL] [Abstract][Full Text] [Related]
13. Advances in chalcones with anticancer activities.
Karthikeyan C; Moorthy NS; Ramasamy S; Vanam U; Manivannan E; Karunagaran D; Trivedi P
Recent Pat Anticancer Drug Discov; 2015; 10(1):97-115. PubMed ID: 25138130
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
15. Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
Xiao J; Gao M; Sun Z; Diao Q; Wang P; Gao F
Eur J Med Chem; 2020 Dec; 208():112830. PubMed ID: 32992133
[TBL] [Abstract][Full Text] [Related]
16. Artemisinin-derived hybrids and their anticancer activity.
Gao F; Sun Z; Kong F; Xiao J
Eur J Med Chem; 2020 Feb; 188():112044. PubMed ID: 31945642
[TBL] [Abstract][Full Text] [Related]
17. A Review: Discovering 1,3,4-oxadiazole and Chalcone Nucleus for Cytotoxicity / EGFR Inhibitory Anticancer Activity.
Patil S; Bhandari S
Mini Rev Med Chem; 2022; 22(5):805-820. PubMed ID: 34477516
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective.
Kumar V; Dhawan S; Girase PS; Awolade P; Shinde SR; Karpoormath R; Singh P
Curr Med Chem; 2021 Oct; 28(33):6805-6845. PubMed ID: 33749549
[TBL] [Abstract][Full Text] [Related]
19. Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships.
Wang R; Chen H; Yan W; Zheng M; Zhang T; Zhang Y
Eur J Med Chem; 2020 Mar; 190():112109. PubMed ID: 32032851
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Antiproliferative Activity of Novel Dehydroabietic Acid-Chalcone Hybrids.
Grigoropoulou S; Manou D; Antoniou AI; Tsirogianni A; Siciliano C; Theocharis AD; Athanassopoulos CM
Molecules; 2022 Jun; 27(11):. PubMed ID: 35684559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
